A phase 2 open-label study of the safety and efficacy of weekly dosing of ATL1102 in patients with non-ambulatory Duchenne muscular dystrophy and pharmacology in mdx mice
Woodcock, Ian R, Tachas, George, Desem, Nuket, Houweling, Peter J, Kean, Michael, Emmanuel, Jaiman, Kennedy, Rachel, Carroll, Kate, de Valle, Katy, Adams, Justine, Lamandé, Shireen R, Coles, Chantal, Tiong, Chrystal, Burton, Matthew, Villano, Daniella, Button, Peter, Hogrel, Jean-Yves, Catling-Seyffer, Sarah, Ryan, Monique M, Delatycki, Martin B, Yiu, Eppie M
Published in PloS one (25.01.2024)
Published in PloS one (25.01.2024)
Get full text
Journal Article